Business Description
Cynata Therapeutics Ltd
ISIN : AU000000CYP7
Total Employee Number:
2Description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.75 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 16.7 | |||||
3-Year EPS without NRI Growth Rate | -6.6 | |||||
3-Year FCF Growth Rate | -23.2 | |||||
3-Year Book Growth Rate | -46.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -439.97 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.39 | |||||
9-Day RSI | 19.87 | |||||
14-Day RSI | 16.65 | |||||
3-1 Month Momentum % | -95.66 | |||||
6-1 Month Momentum % | -95.63 | |||||
12-1 Month Momentum % | -90.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.48 | |||||
Quick Ratio | 2.48 | |||||
Cash Ratio | 2.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.4 | |||||
Shareholder Yield % | -3.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -120.87 | |||||
ROA % | -102.6 | |||||
ROIC % | -487.59 | |||||
3-Year ROIIC % | -425.82 | |||||
ROCE % | -148.31 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.86 | |||||
Price-to-Tangible-Book | 1.2 | |||||
EV-to-EBIT | -0.04 | |||||
EV-to-EBITDA | -0.04 | |||||
EV-to-Forward-Revenue | 13.21 | |||||
EV-to-FCF | -0.04 | |||||
| Price-to-Net-Current-Asset-Value | 1.2 | |||||
| Price-to-Net-Cash | 1.2 | |||||
Earnings Yield (Greenblatt) % | -3333.33 | |||||
FCF Yield % | -280.04 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cynata Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.037 | ||
| Beta | 0.4827 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.12 | ||
| Volatility % | 115.4 | ||
| 14-Day RSI | 16.65 | ||
| 14-Day ATR (A$) | 0.004273 | ||
| 20-Day SMA (A$) | 0.013 | ||
| 12-1 Month Momentum % | -90.97 | ||
| 52-Week Range (A$) | 0.011 - 0.435 | ||
| Shares Outstanding (Mil) | 243.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cynata Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cynata Therapeutics Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-13 10:00 | In 105 days | ||
| Annual report for 2026 | 2026-08-28 | In 27 days | ||
| Second quarter earnings results for 2026 | 2026-02-26 | 0.37 (+7.25%) | ||
| Cynata Quarterly Investor Webinar | 2026-02-04 11:30 | 0.34 (+1.52%) | ||
| General meeting for 2025 | 2025-11-13 10:00 | 0.25 (+4.17%) | ||
| Annual report for 2025 | 2025-08-28 | 0.22 (+2.38%) | ||
| Second quarter earnings results for 2025 | 2025-02-27 | 0.23 (-2.13%) | ||
| General meeting for 2024 | 2024-11-19 10:00 | 0.23 (-8.16%) | ||
| Annual report for 2024 | 2024-08-29 | 0.20 (+0.00%) | ||
| 0.05:1 Stock Split | 2013-10-31 | 0.50 (+0.00%) |
Show
Entries
Cynata Therapeutics Ltd Frequently Asked Questions
What is Cynata Therapeutics Ltd(ASX:CYP)'s stock price today?
The current price of ASX:CYP is A$0.01. The 52 week high of ASX:CYP is A$0.44 and 52 week low is A$0.01.
When is next earnings date of Cynata Therapeutics Ltd(ASX:CYP)?
The next earnings date of Cynata Therapeutics Ltd(ASX:CYP) is 2027-02-26 Est..
Does Cynata Therapeutics Ltd(ASX:CYP) pay dividends? If so, how much?
Cynata Therapeutics Ltd(ASX:CYP) does not pay dividend.
Press Release
Articles on Cynata Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers